Polyclonal Antibody to Epithelial Neutrophil Activating Peptide 78 (ENA78)
CXCL5; SCYB5; Chemokine C-X-C-Motif Ligand 5; Small Inducible Cytokine Subfamily B(Cys-X-Cys),Member 5; Neutrophil-activating peptide ENA-78
- Product No.PAA860Mu02
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- SourcePolyclonal antibody preparation
- HostRabbit
- Potencyn/a
- Ig Type IgG
- PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
- LabelNone
- Immunogen RPA860Mu02-Recombinant Epithelial Neutrophil Activating Peptide 78 (ENA78)
- Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
- TraitsLiquid
- Concentration500µg/mL
- Organism Species MoreSus scrofa; Porcine (Pig)
- ApplicationsWB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies. - DownloadInstruction Manual
- UOM 20µl100µl 200µl 1ml 10ml
- FOB
US$ 97
For more details, please contact local distributors! US$ 227 US$ 324 US$ 810 US$ 3240
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against ENA78. It has been selected for its ability to recognize ENA78 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.5-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
- Antibody Labeling Customized Service
- Protein A/G Purification Column
- Staining Solution for Cells and Tissue
- Positive Control for Antibody
- Tissue/Sections Customized Service
- Phosphorylated Antibody Customized Service
- Western Blot (WB) Experiment Service
- Immunohistochemistry (IHC) Experiment Service
- Immunocytochemistry (ICC) Experiment Service
- Flow Cytometry (FCM) Experiment Service
- Immunoprecipitation (IP) Experiment Service
- Immunofluorescence (IF) Experiment Service
- Buffer
- DAB Chromogen Kit
- SABC Kit
- Long-arm Biotin Labeling Kit
- Real Time PCR Experimental Service
Magazine | Citations |
Journal of Biochemical and Molecular Toxicology | Ameliorative Effects of Curcumin on Fibrinogen-Like Protein-2 Gene Expression, Some Oxido-Inflammatory and Apoptotic Markers in a Rat Model of l-Arginine-Induced Acute Pancreatitis. Pubmed:26862043 |
Journal of Biochemical and Molecular Toxicology | Ameliorative Effects of Curcumin on Fibrinogen-Like Protein-2 Gene Expression, Some Oxido-Inflammatory and Apoptotic Markers in a Rat Model of l-Arginine-Induced Acute Pancreatitis pubmed:26862043 |
OncoTargets and Therapy | The clinical significance of CXCL5 in non-small cell lung cancer. pubmed:29200871 |
Biochimie | Activated CXCL5-CXCR2 axis promotes the migration, invasion and EMT of papillary thyroid carcinoma cells via modulation of β-catenin pathway Pubmed:29471001 |
Cancer Biology & Therapy | Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 … Pubmed: 30404567 |
Respiratory Research | Phospholipase Cε plays a crucial role in neutrophilic inflammation accompanying acute lung injury through augmentation of CXC chemokine production from … Pubmed: 30634975 |
American Journal of Pathology | Interleukin17–CXCR2 axis facilitates breast cancer progression by up-regulating neutrophil recruitment Pubmed: 31654638 |
Bioactive Materials | Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy 34820587 |
Am J Cancer Res | Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma Pubmed:35141005 |